Interleukin-7
IL7proteinIL-7 drives immune activation in acute coronary syndromes via systemic inflammation independent of thrombotic cascade.
Pathway placement
Cascade stepOff-pathway / systemic markers
Confidencelow
RationaleT-cell proliferation and immune activation marker; elevated in ACS but not plaque-rupture-specific.
Also acts inVascular inflammation
Druggability
Not assessed (no mapped human gene target).
Type I vs non-Type I discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I40
C — non-Type-I73
A — assay feasibility68
E — evidence strength30
T1DI (composite)7
Specificity differential (R−C)-32.6
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
No non-Type-I axis evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)
Literature evidence(1)
- Platelet and monocyte activity markers and mediators of inflammation in Takotsubo cardiomyopathy.Heart and vessels · 2011 · PMID 21416113 · doi